PDF Cover

Lusutrombopag Market

The market for Lusutrombopag was estimated at $221 million in 2024; it is anticipated to increase to $326 million by 2030, with projections indicating growth to around $451 million by 2035.

Report ID:DS1802316
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Lusutrombopag
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Lusutrombopag Market Outlook

Revenue, 2024

$221M

Forecast, 2034

$423M

CAGR, 2025 - 2034

6.7%

The Lusutrombopag industry revenue is expected to be around $236.0 million in 2025 and expected to showcase growth with 6.7% CAGR between 2025 and 2034. The growing demand for Lusutrompbopag in the market can be linked to factors like the increase in thromboctopenia cases in patients with chronic liver diseases and the rising use it for treating this ailment. Lusutrompbopag has shown its effectiveness through trials and benefits from significant research and advancements in pharmaceutical technology which has made it a key player, in various treatment scenarios. Moreover the presenceof pertinent medical conditions, escalating clinical urgency and the rise in healthcare expenditures worldwide particularly in developed and emerging economies have played a crucial role, in solidifying the ongoing market importanceof Lusutromboag.

The medication Lusutrommopab is mainly prescribed for treating platelet count in individuals with long term liver issues who are undergoing medical procedures. It functions by attaching to and stimulating the receptor in humans resultig in a rise in platelet production, within the body.

Lusutrombopag market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Lusutrombopag Market Outlook

Market Key Insights

  • The Lusutrombopag market is projected to grow from $221.2 million in 2024 to $423 million in 2034. This represents a CAGR of 6.7%, reflecting rising demand across Chronic Liver Disease, Thrombocytopenia, and Hepatology Disorders.

  • Shionogi & Co Ltd., Novartis International AG, Takeda Pharmaceutical Company Limited are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Japan are the top markets within the Lusutrombopag market and are expected to observe the growth CAGR of 4.4% to 6.4% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 7.7% to 9.2%.

  • Emergence of Tailored Therapies transition is widening cross-selling opportunities across the Lusutrombopag industry ecosystem, helping companies drive stronger adoption of their full product portfolio. This ecosystem pull-through is projected to add $5 million to Lusutrombopag industry product sales in 2025.

  • The Lusutrombopag market is set to add $202 million between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    increasing prevalence of liver diseases, and

    Unmet Medical Needs for Safe Thrombopoietin Receptor Agonist, Lusutrombopag market to expand 91% between 2024 and 2034.

lusutrombopag market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Lusutrombopag - Country Share Analysis

Opportunities in the Lusutrombopag

Collaborating with partners can also help multinational pharmaceutical companies like Lusutrombopag grow their market presence successfully in regions with strict regulations, through strategic partnerships and effective market penetration strategies.

Growth Opportunities in North America and Asia Pacific

Consistently leading the market is North America. Primarily the United States. Which holds a firm grip on the Lusutromabopag sector due to its prominent healthcare industry and strong research and development capabilities. This growth is propelled by pharmaceutical companies that are both increasing the need for and providing the supply for Lusutromabopag. The market is further boosted by stroke patients who are contributing to the demand, for this receptor agonist. Competition in North America is strong as manufacturers from Asia Pacific and Europe aim to establish their presence in the Lusutrombo market. Factors driving this industry include increased awareness about thromboy openia among the public and the convenience of medication, for patients which improves acceptance and adherence.
The Asia Pacific region is establishing itself as a player in the production and use of Lutrombo pag products with countries like Japan and South Korea leading the way in rapid market growth due to several factors such as an aging population and rising cases of liver related conditions causing low platelet counts alongside advancements in healthcare services overall Government efforts to improve pharmaceutical manufacturing also play a vital role, in driving growth in this region.

Market Dynamics and Supply Chain

01

Driver: Rising Global Chronic Liver Disease Prevalence Coupled With Enhanced Diagnostic Adoption Boosting Lusutrombopag Demand

The increasing incidence of chronic liver diseases such as cirrhosis, hepatitis B and C, and non-alcoholic fatty liver disease is also a central driver for the lusutrombopag market. Chronic liver disease often leads to thrombocytopenia (low platelet counts), creating a growing patient pool requiring effective platelet-raising therapies like lusutrombopag, especially ahead of invasive procedures. This trend is also particularly strong in regions with high hepatitis prevalence and aging populations, expanding the target demographic for the drug. At the same time, advancements in diagnostic capabilities and greater clinician awareness are also facilitating earlier and more accurate identification of thrombocytopenia and related complications, prompting greater adoption of targeted treatments. Enhanced diagnostics, such as improved blood screening and liver function tests, enable physicians to more confidently prescribe lusutrombopag, driving its utilization in both hospital and outpatient settings.
Ongoing research and clinical development aimed at broadening lusutrombopag’s therapeutic indications including potential use in other forms of thrombocytopenia beyond chronic liver disease is also a significant growth driver. Pharmaceutical investment in clinical trials and supportive regulatory environments are also enabling the exploration of new patient segments and expanded label approvals. This trend is also buoyed by a broader industry shift toward thrombopoietin receptor agonist therapies with improved safety and efficacy profiles compared to older agents, increasing clinician confidence and widening prescriber base. As trials succeed and approvals expand, lusutrombopag’s addressable market grows, strengthening its competitive positioning and fostering deeper market penetration, particularly in regions with robust healthcare infrastructure and reimbursement support for innovative treatments.
02

Restraint: High Cost and Limited Cost-Effectiveness Perceptions Restrict Lusutrombopag Market Adoption

The relatively high price of lusutrombopag and concerns about its cost-effectiveness remain major restraints on market growth. Health technology assessments have identified that although lusutrombopag reduces platelet transfusions, the high drug cost often outweighs savings from avoided procedures, resulting in poor cost-effectiveness ratios compared with standard care in some healthcare systems. This dynamic limits reimbursement support, especially in price-sensitive and public payer markets, thereby reducing demand among hospitals and clinicians. For example, in the UK health assessment, both lusutrombopag and its competitor were shown to be more expensive over a lifetime than no thrombopoietin receptor agonist, with the incremental benefit not justifying the higher cost, dampening prescribing uptake and market revenue growth.
03

Opportunity: Untapped Segments and Technological Innovations

The potential benefits that Lusutromabpag offers in managing thromcytopenia. A condition marked by platelet levels. Especially among individuals with chronic liver issues undergoing invasive treatments are notable. The promising performance of this medication and the increasing prevalence worldwide of liver ailments indicate an opportunity for expansion in an underexplored market segment. Nations with rates of liver diseases, like China and India might offer profitable business prospects.
Lusutromboapg is an option in treating thrombosytopenia that could see improvements through continued pharmaceutical research and technological advancements in delivery methods and formulations. Progress in pharmaceuticals focusing on increasing drug effectiveness and minimizing side effects to boost adherence could lead to substantial growth, in the market.
04

Challenge: Intense Competitive Pressures and Narrow Indication Scope Constrain Lusutrombopag Market Expansion

Lusutrombopag faces stiff competition from established thrombopoietin receptor agonists and potential biosimilars, which can limit its market share and pricing power. Generic erosion of other TPO-RAs in key markets, like the U.S., erodes overall category margins, pressuring lusutrombopag to compete on price and differentiation. Additionally, its approved use is narrowly confined to thrombocytopenia associated with chronic liver disease prior to invasive procedures, restricting total addressable patients relative to broader-indication therapies. These competitive and label constraints reduce demand growth and slow revenue expansion as clinicians may preferentially use alternatives with wider indications or lower costs.

Supply Chain Landscape

1

Raw Material Procurement

Eisai Co. LtdTakeda Pharmaceutical Company
2

API Production

Shionogi & Co. LtdEisai Co. Ltd
3

Formulation & Packaging

Takeda Pharmaceutical CompanyShionogi & Co. Ltd
4

Distribution & End-User

Specialty PharmacyHospital PharmacyRetail Pharmacy
Lusutrombopag - Supply Chain

Use Cases of Lusutrombopag in Chronic Liver Disease & Thrombocytopenia

Chronic Liver Disease : In chronic liver disease, lusutrombopag is used as an oral thrombopoietin receptor agonist to safely increase platelet counts in patients with advanced hepatic dysfunction. Hepatologists and gastroenterologists prescribe lusutrombopag prior to invasive procedures such as endoscopy or liver biopsy to mitigate bleeding risk associated with low platelets. Its mechanism of stimulating megakaryocyte production enhances platelet generation without the need for repeated platelet transfusions. Patients benefit from improved procedural readiness, reduced transfusion requirements, and a more predictable rise in platelet count, making lusutrombopag a valuable therapeutic option in managing chronic liver disease complications.
Thrombocytopenia : For thrombocytopenia, particularly in patients with chronic liver disease‑related low platelet counts, lusutrombopag is primarily used as an oral treatment to elevate platelet levels ahead of medical interventions. Hematologists value it for its targeted action on thrombopoietin receptors, which stimulates bone marrow to produce platelets, reducing the risk of bleeding during diagnostic or surgical procedures. Compared to platelet transfusions, oral lusutrombopag offers a noninvasive alternative with fewer logistical challenges, enhanced patient comfort, and lower risk of transfusion‑related reactions, improving both clinical workflow and patient outcomes.
Hepatology Disorders : In the broader category of hepatology disorders, lusutrombopag supports patients with compromised liver function who develop secondary thrombocytopenia, often complicating treatment plans. This includes individuals undergoing therapy for cirrhosis or portal hypertension where platelet counts are insufficient for safe clinical management. By increasing platelet production, lusutrombopag helps clinicians optimize patient readiness for therapeutic procedures, maintain treatment schedules, and reduce hospital stays. Its oral administration and predictable efficacy are particularly advantageous in outpatient hepatology practices, where minimizing hospital admissions and invasive interventions is a priority.

Recent Developments

Recent strategic developments for lusutrombopag focus on expanding real-world evidence and positioning within thrombopoietin receptor agonist therapies. Increased clinical trial activity and publication of safety data are strengthening physician confidence and supporting payer discussions in hematology and liver disease treatment pathways. A key market trend is personalized medicine adoption, where platelet management is tailored using predictive diagnostics and biomarkers. Incorporating pharmacoeconomic assessments and value-based pricing strategies is also shaping formulary access, enhancing competitive standing in the thrombocytopenia drug market.

December 2024 : Shinogi Inc., a producer in the pharmaceutical industry for Lusutrombobap medication officially received FDA endorsement for a fresh application in pediatrics. This move expands its market reach. Provides innovative therapy choices, for children suffering from thromboyctopenia.
October 2024 : Novartis Pharmaceuticals showed promising outcomes in a phase III study that compared Lusutrom bop ag with alternative throm Bop Oietin receptor activators. These findings suggest effectiveness and safety features and pave the way, for potential joint treatment options.
August 2024 : Shionogi Inc.

Impact of Industry Transitions on the Lusutrombopag Market

As a core segment of the Pharmaceutical industry, the Lusutrombopag market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Tailored Therapies and Rise in Biomedical Research have redefined priorities across the Pharmaceutical sector, influencing how the Lusutrombopag market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Emergence of Tailored Therapies

The field of biotechnology has seen a shift towards creating personalized treatments lately. The emergence of Lusutrombopag stands out as an example tailored for adults dealing with chronic liver conditions. This development showcases how pharmaceutical companies have met a demand that was previously unaddressed, utilizing the characteristics of this compound. This evolution has not only led to better results for patients but has also spurred economic expansion, in healthcare through the introduction of specialized treatments that come with higher price tags. The costs associated with hospital stays and managing illnesses have significantly decreased due to the proven effectiveness Lusutromtopag has shown in treating thromobocytopenia. This move, towards tailored medical care highlights the promise that individualized healthcare solutions hold for patients.
02

Rise in Biomedical Research

The rise in biomedical research reflects a broader industry transition toward innovation-driven drug development, directly supporting advances such as lusutrombopag. Pharmaceutical and biotechnology companies are increasingly prioritizing targeted therapies that address specific unmet clinical needs, including thrombocytopenia associated with chronic liver disease. This shift is supported by higher R&D spending, improved translational research models, and closer collaboration between academia, biotech firms, and large pharmaceutical players. For example, advances in platelet biology and thrombopoietin receptor signaling have enabled more precise drug design, reducing reliance on transfusions. Contract research organizations and clinical trial technology providers also benefit, as demand rises for specialized trials in hepatology and hematology. Overall, this transition accelerates innovation cycles, improves therapeutic precision, and strengthens the ecosystem supporting niche drugs like lusutrombopag.